Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The prospects for clinical use of palbociclib, a new oral selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, in patients with hormone-positive advanced breast cancer (BC) are discussed. The article presents the results of clinical studies, which show that the palbociclib-based combinations significantly increase the progression-free survival rates in this category of patients. The main candidates for palbociclib-based combination therapy can be patients with hormone-positive, HER2-negative breast cancer who had previously been recommended for chemotherapy due to the spread of the disease and the threat of a visceral crisis. Strong arguments in favor of the appointment of this treatment regimen are manageable safety profile of the palbociclib-based combination and a higher progression-free survival rate in comparison with chemotherapy.

Full Text

Restricted Access

About the authors

L. G Zhukova

FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH

Email: zhukova.lyudmila@rambler.ru
MD, Leading Researcher at the Department of Chemotherapy and Combined Treatment of Malignant Tumors

E. I Chichikov

FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH

O. O Gordeeva

FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH

D. A Filonenko

FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH

References

  1. Arpino G., Green S.J., Allred D.C., Lew D., Martino S., Osborne C.K., Elledge R.M. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study Clin. Cancer Res. 2004;10(17):5670-76.
  2. Barnes D.M., Gillett C.E. Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 1998;52(1-3):1-15.
  3. Brodie A., Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin. Cancer Res. 2011;17(13):4208-13.
  4. Chow L.W.C., Lam C.-K., Loo W.T.Y. A phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer. Cancer Res. 2015;75(Suppl. 9):Abstr. P6-11-04.
  5. Cottu P., et al. Letrozole and Palbociclibversus 3rd Generation Chemotherapy as Neoadjuvant Treatment of Luminal Breast Cancer: Results of the UNICANCER-NeoPALStudy. Ann. Oncol. 2017;28(Suppl. 5):Abstr. LBA_9.
  6. Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N., Colleoni M., DeMichele A., Loi S., Verma S., Iwata H., Harbeck N., Zhang K., Theall K.P, Jiang Y., Bartlett C.H., Koehler M., Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-39.
  7. Dean J.L., Thangavel C., McClendon A.K., Reed C.A, Knudsen E.S. Therapeutic CDK4/6inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018-32.
  8. DeMichele A.,Clark A.S., Tan K.S., Heitjan D.F., Gramlich K., Gallagher M., Lal P., Feldman M., Zhang P, Colameco C., Lewis D., Langer M., Goodman N., Domchek S., Gogineni K., Rosen M., Fox K., O'Dwyer P. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 2015;21(5):995- 1001.
  9. Dickson M.A. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin. Cancer Res. 2014;20(13):3379-83.
  10. Dickson M.A., Schwartz G.K. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009;16(2):36-43.
  11. Dieci M.V., Arnedos M., Delaloge S., Andre F. Quantification of residual risk of relapse in breast cancer patients optimally treated. Breast. 2013;22(Suppl 2):S92-5.
  12. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., Ginther C., Atefi M., Chen I., Fowst C., Los G., Slamon D.J. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
  13. Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K., Harbeck N., Lipatov O.N., Walshe J.M., Moulder S., Gauthier E., Lu D.R., Randolph S., Dieras V., Slamon D.J. Palbociclib and Letrozole in Advanced Breast Cancer. N. Engl. J. Med. 2016;375(20):1925-36.
  14. Finn R.S., Aleshin A., Slamon D.J. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17.
  15. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004;3(11):1427-38.
  16. Harbeck N., Iyer S., Turner N., Cristofanilli M., Ro J., Andre F., Loi S., Verma S., Iwata H., Bhattacharyya H., Puyana Theall K., Bartlett C.H., Loibl S. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann. Oncol. 2016;27(6):1047-54.
  17. Lange C.A., Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr. Relat. Cancer. 2011;18(4):19-24.
  18. Malorni L., et al. A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial). ASCO 2017. Abstr. 1002.
  19. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.
  20. Miller T.W., Balko J.M., Fox E.M., Ghazoui Z., Dunbier A., Anderson H., Dowsett M., Jiang A., Smith R.A., Maira S.M., Manning H.C., Gonzâlez-Angulo A.M., Mills G.B., Higham C., Chanthaphaychith S., Kuba M.G., Miller W.R., Shyr Y., Arteaga C.L. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4):338-51.
  21. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009;28(33):2925-39.
  22. Slamon D.J., et al. Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18). J. Clin. Oncol. 2015;33(suppl):abstr 570.
  23. Thangavel C., Dean J.L., Ertel A., Knudsen K.E., Aldaz C.M., Witkiewicz A.K., Clarke R., Knudsen E.S. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr. Relat. Cancer. 2011;18(3):333-45.
  24. VanArsdale T., Boshoff C., Arndt K.T., Abraham R.T. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin. Cancer Res. 2015;21(13):2905-10.
  25. Zardavas D., Phillips W.A., Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res. 2014;16(1):201.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies